| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2007;115:1703-1709.)
© 2007 American Heart Association, Inc.
Arrhythmia/Electrophysiology |
From the Department of Cardiac Electrophysiology and Clinical Pacing Hôpital, University of Bordeaux and Grenoble, Grenoble, France (S.G., P.D., J.C.); Inserm ERI 17, Sleep Laboratory and Hypoxia Pathophysiology (HP2) Laboratory, University Hospital and Joseph Fourier University, Grenoble, France (J.-L.P., P.L.); Department of Cardiac Electrophysiology and Clinical Pacing, Papworth Hospital, Cambridge, UK (F.M.); and ELA Medical, Clinical Research Department, CA La Boursidière, Le Plessis-Robinson, France (Y.P.)
Correspondence to Professor Patrick Lévy, Laboratoire dExploration Fonctionnelle Cardio-Respiratoire, CHU, Grenoble, 38043 France. E-mail PLevy{at}chu-grenoble.fr
Received August 22, 2006; accepted January 19, 2007.
Background Cardiovascular diseases leading to pacemaker implantations are suspected of being associated with a high rate of undiagnosed sleep apnea syndrome (SAS). We sought to determine the prevalence and consequences of SAS in pacemaker patients according to pacing indications: heart failure, symptomatic diurnal bradycardia, and atrioventricular block.
Methods and Results Ninety-eight consecutive patients (mean age, 64±8 years) not known to have sleep apnea were included; 29 patients were paced for dilated cardiomyopathy (29%), 33 for high-degree atrioventricular block (34%), and 36 for sinus node disease (37%). All underwent Epworth Sleepiness Scale assessment and polysomnography with the pacemaker programmed to right ventricular DDI pacing mode (lower pacing rate, 50 pulses per minute). SAS was defined as an apnea-hypopnea index
10/h. Mean Epworth Sleepiness Scale was in the normal range (7±4), although 13 patients (25%) had an abnormal score >11/h. Fifty-seven patients (59%) had SAS; of these, 21 (21.4%) had a severe SAS (apnea-hypopnea index >30/h). In patients with heart failure, 50% presented with SAS (mean apnea-hypopnea index, 11±7) compared with 68% of patients with atrioventricular block (mean apnea-hypopnea index, 24±29) and 58% with sinus node disease (mean apnea-hypopnea index, 19±23).
Conclusions In paced patients, there is an excessively high prevalence of undiagnosed SAS (59%). Whether treating SAS would have changed the need for pacing is unknown. Treatment effects should be further evaluated particularly because these patients are less symptomatic than typical SAS patients. In any case, SAS should be systematically searched for in paced patients owing to potential detrimental effects on their cardiovascular evolution.
Related Article:
This article has been cited by other articles:
![]() |
V. K. Somers, D. P. White, R. Amin, W. T. Abraham, F. Costa, A. Culebras, S. Daniels, J. S. Floras, C. E. Hunt, L. J. Olson, et al. Sleep Apnea and Cardiovascular Disease: An American Heart Association/American College of Cardiology Foundation Scientific Statement From the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing In Collaboration With the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health) Circulation, September 2, 2008; 118(10): 1080 - 1111. [Full Text] [PDF] |
||||
![]() |
C. M. Ryan, S. Juvet, R. Leung, and T. D. Bradley Timing of Nocturnal Ventricular Ectopy in Heart Failure Patients With Sleep Apnea Chest, April 1, 2008; 133(4): 934 - 940. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |